Compare FPF & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPF | CDNA |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2014 |
| Metric | FPF | CDNA |
|---|---|---|
| Price | $18.85 | $20.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 186.7K | ★ 765.2K |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 8.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $357,998,000.00 |
| Revenue This Year | N/A | $14.47 |
| Revenue Next Year | N/A | $11.35 |
| P/E Ratio | ★ N/A | $16.94 |
| Revenue Growth | N/A | ★ 14.46 |
| 52 Week Low | $13.91 | $10.96 |
| 52 Week High | $18.09 | $25.55 |
| Indicator | FPF | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.80 | 56.75 |
| Support Level | $18.82 | $20.09 |
| Resistance Level | $19.00 | $21.20 |
| Average True Range (ATR) | 0.14 | 1.06 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 65.45 | 79.76 |
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.